On December 28, 2021, the FDA updated the emergency use authorization (EUA) for COVID-19 convalescent plasma. The update limits the authorization to the use of COVID-19 convalescent plasma with high titers of anti -SARS-CoV-2 antibodies for the treatment of COVID-19 in patients with immunosuppressive disease or who are receiving immunosuppressive treatment. Additionally, to help assure the manufacture of high titer COVID-19 convalescent plasma, the revisions to the EUA define acceptable tests and increase qualifying result cutoffs to be used for manufacturing COVID-19 convalescent plasma with high titers of anti-SARS-CoV-2 antibodies.
We are currently evaluating our options to determine if we can provide additional testing services using one of the newly defined assays. Please reach out to your customer service manager if your organization is considering CCP testing under the updated guidelines.
Beginning June 1, 2020 all 5 CTS laboratories will being transitioning from the Grifols Procleix Ult...
Through communications with our clients, CTS is aware of the current national blood shortage. We rea...
CTS originally communicated that Tampa will convert from the current Grifols Ultrio Plus NAT triplex...
As previously mentioned in Zika communications distributed on September 21 and October 12, 2018; ord...
In response to the FDA guidance document for Babesia, CTS will implement the licensed Grifols ...
National Blood Donor Month has been observed in January since 1970, with the goal of increasing bloo...